Interstitial Lung Disease News

Almost 90% of Americans are unaware of the symptoms that signal pulmonary fibrosis due to the disease’s rarity, according to a Pulmonary Fibrosis Foundation survey.

Researchers characterized several pulmonary manifestations of ulcerative colitis, although they noted these lung diseases only occurred among 5% of their cohort, according to study results published in CHEST.

About half of patients with interstitial lung abnormalities had suspected interstitial lung disease, with these patients having greater symptoms and more unfavorable clinical outcomes, according to study results.

The FDA granted orphan drug designation to INS018_055, an anti-fibrotic small molecule inhibitor, for treating patients with idiopathic pulmonary fibrosis, according to a press release from the drug’s manufacturer.

Because interstitial lung disease is often associated with an older patient population, there is limited knowledge on how ILD impacts young women who are pregnant, according to a review published in CHEST.

Patients with systemic sclerosis who report more severe reflux symptoms demonstrate worse interstitial lung disease outcomes despite receiving standard therapy, according to data published in Arthritis Care & Research.

The FDA has granted Orphan Drug Designation to belimumab, a B-cell inhibiting monoclonal antibody, for the potential treatment of systemic sclerosis, according to a press release from GlaxoSmithKline.

Compared with high-resolution CT, chest radiography appeared less accurate in detecting interstitial lung disease, according to a study published in Annals of the American Thoracic Society.

A higher BMI did not appear to increase risk for sarcoidosis, according to study results published in CHEST.

The FDA granted orphan drug designation to ifenprodil for the treatment of patients with idiopathic pulmonary fibrosis, according to a press release from the drug’s manufacturer.